Related Experiment Video
Updated: May 27, 2026

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin
A Polymeris1, K Doumouchtsis, E Grapsa
1Second Division of Endocrinology, Alexandra Hospital, Athens, Greece. antonispolymeris@yahoo.gr
Insights
In hemodialysis patients, high parathyroid hormone (PTH) levels correlate with bone metabolism markers. However, elevated leptin levels showed no association with bone metabolism or bone density in this study.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Bone metabolism disorders are common in hemodialysis (HD) patients, with parathyroid hormone (PTH) playing a central role.
- Leptin levels are often elevated in renal failure, but their impact on bone metabolism remains unclear.
- This study investigates bone mineral density (BMD) and bone metabolism in relation to PTH, 25-hydroxyvitamin D3 (25OHD3), and leptin in HD patients.
Purpose of the Study:
- To examine the relationship between serum PTH, 25OHD3, and leptin levels and their association with bone metabolism and BMD in hemodialysis patients.
- To determine if leptin levels correlate with bone turnover markers or bone density in this patient population.
Main Methods:
- Measured bone alkaline phosphatase (bSAP), N-telopeptide of type 1 collagen (NTx), PTH, 25OHD3, and leptin in 37 HD patients.
- Evaluated Body Mass Index (BMI) and BMD at the lumbar spine (LS) and femoral neck (FN) using dual-energy X-ray absorptiometry (DXA).
- Employed simple regression analysis for statistical evaluation.
Main Results:
- Osteopenia and osteoporosis were prevalent, affecting 32.1%-50% and 14.3%-21.4% of patients, respectively.
- Bone markers, PTH, phosphorus, and leptin levels were elevated; 25OHD3 levels were low.
- PTH positively correlated with bone markers and Z scores at LS and FN, while leptin showed no significant correlation with bone metabolism or BMD (except with BMI).
Conclusions:
- Hemodialysis patients exhibit increased bone metabolism markers linked to high serum PTH levels.
- Elevated serum leptin in these patients is not associated with altered bone metabolism or density.
- The duration of hemodialysis did not significantly impact bone density in the studied cohort.
Background:
Bone metabolism disorders in hemodialysed patients (HD) involve several humoral factors, of which PTH plays the central role. Leptin is usually found increased in renal failure and its link with bone metabolism has not been elucidated. We investigated the BMD and bone metabolism in association with serum PTH, 25OHD3 and leptin in HD patients.
Methods:
We measured bone alkaline phosphatase (bSAP), cross linked N telopeptide of type 1 collagen (NTx), PTH, 25OHD3 and leptin in 37 HD patients. We also evaluated BMI and BMD in lumbar spine (LS) and in femoral neck (FN) by DXA. Statistical evaluations were based on simple regression analysis.
Results:
1) Osteopenia was found in 32,1% in LS and 50% in FN and osteoporosis in 14.3% and 21.4% of our patients, respectively. LS or FN Z score was not related to HD duration. 2) Bone markers, PTH, phosphorus and leptin levels were increased. 3) 25OHD3 was low and was not related to NTx, bSAP or PTH. 4) PTH correlated with bone markers and Z score in LS and FN. 5) Leptin had no correlation with bone markers or Z score (except BMI).
Conclusions:
In our hemodialysed patients bone metabolism markers were increased in relation with high serum PTH levels. The observed high serum leptin was not associated with bone metabolism. Additionally the duration of hemodialysis did not appear to affect bone density.
Related Concept Videos
Bone Remodeling
Chronic Kidney Disease III: Interprofessional Care
Skeleton and Calcium Homeostasis
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hemodialysis III: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations